Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 12/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1616147 | 0.83 | MCHR1 (0.37) | MCHR1PFKFB3 | |
| SCHEMBL1616456 | 0.82 | RET (0.36) | MCHR1PFKFB3 | |
| SCHEMBL1616568 | 0.80 | ADRA1A (0.38) | MCHR1PFKFB3 | |
| SCHEMBL2905912 | 0.77 | MCHR1 (0.39) | MCHR1EGFRPFKFB3HTR1ADRD2 | |
| SCHEMBL1614383 | 0.77 | KDM4E (0.36) | MCHR1PFKFB3 | |
| SCHEMBL2243192 | 0.76 | ACHE (0.42) | MCHR1EGFRPFKFB3HTR1A | |
| SCHEMBL2242783 | 0.75 | CYP2C19 (0.48) | — | |
| SCHEMBL1616695 | 0.74 | ALDH1A1 (0.42) | — | |
| SCHEMBL2242647 | 0.74 | ALDH1A1 (0.46) | P2RX7 | |
| SCHEMBL2243251 | 0.74 | MEN1 (0.41) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923561-B2 | Quinolines | HOFFMANN-LA ROCHE INC. (US) | 2011-04-12 | — | — | US | claimed |
| US-20080146567-A1 | QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-19 | — | — | US | claimed |
| US-7923561-B2 | Quinolines | HOFFMANN-LA ROCHE INC. (US) | 2011-04-12 | — | — | US | disclosed |
| EP-2099763-B1 | 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| EP-2099763-A1 | 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-09-16 | — | — | EP | disclosed |
| US-20080146567-A1 | QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-19 | — | — | US | disclosed |
| WO-2008068157-A1 | 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146567-A1 | QUINOLINES | HTR5A, HTR2B, HTR2C | MCHR1 292/4885EGFR 4521/4885PFKFB3 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.